FDA Accepts NDA Filing for Retigabine

Share Name	Share Symbol	Market	Type
Valeant Pharmaceuticals International, Inc.	AMEX:VRX	AMEX	Common Stock

Share Name

Share Symbol

Market

Type

Valeant Pharmaceuticals International, Inc.

AMEX:VRX

AMEX

Common Stock

Price Change

% Change

Share Price

High Price

Low Price

Open Price

Shares Traded

Last Trade

0.00

0.00%

FDA Accepts NDA Filing for Retigabine

30/12/2009 1:00pm

PR Newswire (US)

Valeant Pharmaceuticals International, Inc. (AMEX:VRX)
Historical Stock Chart

From May 2019 to May 2024

Click Here for more Valeant Pharmaceuticals International, Inc. Charts.

MAA successfully validated by EMEA ALISO VIEJO, Calif., Dec. 30 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE:VRX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) seeking marketing approval for the investigational drug retigabine, a neuronal potassium channel opener for the adjunctive treatment for adult epilepsy patients with partial-onset seizures. In addition, the European Medicines Agency (EMEA) confirmed on November 17, 2009 that the MAA was successfully validated thus enabling the MAA review to commence. The filings were submitted on October 30, 2009. About Retigabine Retigabine is a neuronal potassium channel opener currently in late-stage development as an adjunctive treatment for adult patients with partial-onset seizures. In Phase III epilepsy trials, retigabine reduced seizure rates compared to patients taking placebo. The most common adverse reactions (incidence greater than or equal to 5% and twice placebo) across all completed trials to date are dizziness, fatigue, confusional state, vertigo, tremor, coordination abnormal, diplopia (double vision), disturbance in attention, asthenia (weakness), and visual blurring. Retigabine Important Note As an investigational drug, retigabine has not been found by the Food and Drug Administration (FDA) or any other regulatory agency to be safe or effective in the treatment of any disease or illness. It may not be commercialized in the United States unless and until the FDA has approved a NDA. Similar restrictions apply in other countries. Collaboration Agreement with GlaxoSmithKline Valeant has a worldwide License and Collaboration Agreement with GlaxoSmithKline (NYSE:GSK), to develop and commercialize retigabine. Valeant will collaborate with GSK on the development and marketing of retigabine in the United States, Australia, New Zealand, Canada and Puerto Rico (Collaboration Territory) and GSK has an exclusive license to develop and commercialize retigabine in countries outside of the Collaboration Territory and certain backup compounds to retigabine worldwide. About Valeant Valeant Pharmaceuticals International (NYSE:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at http://www.valeant.com/. (Logo: http://www.newscom.com/cgi-bin/prnh/20081125/VALEANTLOGO) Contact: Laurie W. Little Valeant Pharmaceuticals 949-461-6002 http://www.newscom.com/cgi-bin/prnh/20081125/VALEANTLOGO http://photoarchive.ap.org/ DATASOURCE: Valeant Pharmaceuticals International CONTACT: Laurie W. Little of Valeant Pharmaceuticals, +1-949-461-6002, Web Site: http://www.valeant.com/

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

VRX Valeant Pharmaceuticals International, Inc.